



Anergis SA Announces the Appointments of Jean-Michel Dayer, M.D., Raif S. Geha, M.D. and Stefan Kaufmann Ph.D. to the Company's International Scientific Advisory Board

LAUSANNE, Switzerland – May 11, 2009 – Anergis SA, a clinical-stage biopharmaceutical company developing innovative specific immunotherapy against allergies, today announced the appointments of Jean-Michel Dayer, M.D., Raif S Geha, M.D., and Stefan Kaufmann, Ph.D. to the Company's International Scientific Advisory Board.

“Dr. Dayer, Dr. Geha and Dr. Kaufmann together and individually bring extensive expertise and experience in immunology and allergology, adding significant knowledge depth to the Company in complementary areas of the immune system and of its modulation. This was essential because we expect our International Scientific Advisory Board to play a key role in supporting the Company's scientific orientations and in optimizing the research and development of novel immunotherapy products based on our Contiguous Overlapping Peptide technology”, said François Spertini, M.D., founder of Anergis and Chairman of the Company's International Scientific Advisory Board.

“We are delighted and honored that Dr. Dayer, Dr. Geha and Dr. Kaufmann have joined our International Scientific Advisory Board. Together with François Spertini, M.D., we can count on a very strong panel of scientific and medical experts to guide the advancement of our current and future clinical and preclinical projects and technologies” said Christophe Reymond, Ph.D., CSO of Anergis.

Jean-Michel Dayer, M.D. is Emeritus Professor of Medicine of the University of Geneva (2007). Dr. Dayer trained in Internal Medicine in Geneva. In 1974, he joined the Arthritis Unit, MGH, HMS (Professor S. M. Krane), Assistant Professor of Medicine in 1978. Back at the Faculty of Medicine in Geneva (1981), he was Head/ Division of Immunology & Allergy, Geneva University Hospital (1993), full Professor of Medicine (1996), Vice-Dean (1999) and Chairman of the Section of Clinical Medicine, Faculty of Medicine, Geneva (2004). Dr. Dayer was among the first to initiate the field of pro- and anti-inflammatory cytokines in chronic inflammatory diseases, and to establish a link between immune system, cytokines and matrix degradation. He identified the factor IL-1 and TNF which stimulates collagenase and PGE₂ in synovial cells, and unravelled the mechanism of its production - outcome of the interaction between monocytes and lymphocytes. He has 319 publications in peer-reviewed journals and numerous review articles and book chapters. Dr. Dayer received the Max Cloëtta Award, the Carol Nachman award the Novartis- ILAR Rheumatology, the EULAR Prize and the Japan Rheumatism Foundation International RA Award and presented the Heberden Lecture. He is Doctor honoris causa of Lund University (Sweden) and Honorary Member of the Italian Rheumatology Society. He was President of the European Cytokine Society, International Cytokine Society and Swiss Society of Allergy & Immunology, councillor within the Scientific Committee of the Swiss National Science Foundation, and is presently a member of the Scientific Committee of EULAR and Master of the American College of Rheumatology.

Raif Salim Geha, M.D. received his M.D. degree in 1969 from the American University of Beirut, Lebanon, and trained in Pediatrics and Immunology at Boston Children's Hospital and Harvard Medical School under a Fogarty International Fellowship. He became Head of the Division of Allergy at Children's in 1976 and was appointed Professor of Pediatrics at Harvard Medical School in 1987, where he now holds the James L. Gamble chair of Pediatrics. Since 1988, he has headed the Combined Allergy, Immunology, Rheumatology and Dermatology Division at Children's. Dr. Geha's research interests are in the fields of primary immunodeficiency, T cell activation, IgE isotype switching, and mechanisms of atopic dermatitis. He has contributed to date more than 315 original articles, 150 reviews, several monographs and a book. His publications have appeared in Cell, Immunity, Nature, Molecular Cell, PNAS, J. Experimental Medicine, J. of Immunol. and JACI. Dr. Geha has received the Mead Johnson Award for Pediatric Research, the Kuwait Foundation for the Advancement of Sciences Prize, and the Scientific Achievement Award from the International



Association of Allergology and Clinical Immunology. He has served on a number of NIH study sections and on the NIAID council, has been a director of the American Board of Allergy and Immunology, was elected to the American Society of Clinical Investigation and the American Association of Physicians, has presided over the Clinical Immunology Society and chairs the IUIS Committee on Immunodeficiency. Over the past 25 years Dr. Geha has trained more than 100 postdoctoral fellows, many of whom have risen to leadership positions in the fields of allergy and Immunology.

Stefan H.E. Kaufmann, Ph.D. is founding director and director of the Department of Immunology of the Max Planck Institute for Infection Biology in Berlin, professor for microbiology and immunology at the Charité, Humboldt University, Berlin, and honorary professor at the University Clinics Benjamin Franklin, Free University Berlin. Past president and honorary member of the German Society for Immunology. President of the European Federation of Immunological Societies. Vice President of the International Union of Immunological Societies (IUIS). Born 1948 in Ludwigshafen am Rhein. Studied biology at the Johannes Gutenberg University of Mainz, 1977 PhD. Scientific interests: immunity to bacterial pathogens with emphasis on tuberculosis and rational vaccine design. Numerous scientific awards. Doctor Honoris Causa from Université de la Méditerranée, Aix-Marseille II. More than 600 publications mostly in high-ranking journals. Highly cited immunologist (ISI Thomson).

About Anergis SA

Anergis SA is a clinical-stage Swiss-based biopharmaceutical company specializing in the discovery and development of novel specific immunotherapy products. Allergy is the most prevalent and the fastest growing chronic condition in the industrialized world with over 300 million people affected. Current specific immunotherapy ("SIT") remains underused due to its long duration (3-5 years of treatment) and safety risks. Anergis' objective is to make SIT treatments available to many more allergic patients than today, by providing novel safe and fast immunotherapeutic products. Anergis possesses a unique know-how and an exclusive license to the technology of Contiguous Overlapping Peptides ("COPs") developed jointly by the University of Lausanne, Switzerland (UNIL), the Federal Institute of Technology (EPFL) and the Centre Hospitalier Universitaire Vaudois (CHUV). The technology of COPs allows the identification and development of uniquely profiled proprietary products intended for ultra-fast and safe desensitization. In the past years, Anergis has identified and studied proprietary COPs targeting bee venom and tree pollen allergies, both in animals and in humans. These studies have clearly established the safety, tolerability and immunogenicity of the COP technology.

Contacts:

Anergis SA
Vincent Charlon, CEO
Christophe Reymond, CSO
info@anergis.ch

www.anergis.ch